News
CAMP TECSON, Philippines — U.S. Army medics partnered with Philippine Army soldiers for a medical evacuation-focused subject matter expert exchange as part of Exercise Salaknib 2025, March 25 ...
Investigators assessed silmitasertib monotherapy in patients who had failed first-line hedgehog pathway inhibitors, with 27.3% also failing second-line PD-1 inhibitors such as cemiplimab (Libtayo) or ...
The vast majority of Medicare's top-selling brand-name oncology drugs in 2022 provided high added therapeutic benefit. Ten drugs were classified as low or no added therapeutic benefit compared ...
Panelists discuss how the five-year prognosis for advanced non-small cell lung cancer (NSCLC) has improved with PD-1 inhibitors, showing promising overall survival (OS) and progression-free survival ...
Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945’s potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company ...
and cemiplimab (Libtayo), an anti–PD-1 agent, in patients with advanced melanoma. 1 The first-in-human, phase 1, open-label, dose-escalation and cohort expansion trial sought to evaluate the safety ...
Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company ...
Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo.
Key products like EYLEA, Libtayo, and Dupixent propelled the company’s growth. Dupixent continues to be a major success, treating over a million patients worldwide, and it may find new uses.
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results